ORGO

EX-99.1

2 orgo-ex99_1.htm

EX-99.1

EX-99.1

Exhibit 99.1

FOR IMMEDIATE RELEASE

Organogenesis Holdings Inc. Reports Third Quarter 2026 Financial Results

CANTON, Mass., (November 5, 2026) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine and tissue innovations company focused on empowering healing through the development, manufacture, and sale of product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets, today reported financial results for the third quarter ended September 30, 2026.

Third Quarter 2026 Financial Results Summary:

• Net revenue of $45.5 million for the third quarter of 2026, a decrease of $105.0 million compared to net revenue of $150.5 million for the third quarter of 2025. Net revenue for the third quarter of 2026 consists of:

o Net revenue from Advanced Wound Care products of $38.2 million, a decrease of 73% from the third quarter of 2025.

o Net revenue from Surgical & Sports Medicine products of $7.3 million, a decrease of 19% from the third quarter of 2025.

• Net loss of $29.6 million for the third quarter of 2026, compared to net income of $21.6 million for the third quarter of 2025, an increase in net loss of $51.2 million.

• Adjusted net loss of $29.3 million for the third quarter of 2026, compared to adjusted net income of $23.2 million for the third quarter of 2025, an increase in adjusted net loss of $52.5 million.

• Adjusted EBITDA loss of $22.4 million for the third quarter of 2026, compared to Adjusted EBITDA income of $30.1 million for the third quarter of 2025, an increase in Adjusted EBITDA loss of $52.5 million.

“We continue to strengthen our position as a leader in regenerative medicine as customers choose a partner and products they trust,” said Gary S. Gillheeney, Sr., President, Chief Executive Officer and Chair of the Board for Organogenesis. “Third quarter revenue increased sequentially, and our market share gains are broad-based across our portfolio. We are defining a sustainable future for advanced wound care as we emerge from the market reset a stronger company anchored by evidence-based living cell products that we believe will be the cornerstone of the market going forward.”

Third Quarter 2026 Financial Results:

Three Months Ended September 30,

Change

2026

2025

$

%

(in thousands, except for percentages)

Advanced Wound Care

$

38,152

$

141,451

$

(103,299

)

(73

%)

Surgical & Sports Medicine

7,305

9,036

(1,731

)

(19

%)

Net product revenue

$

45,457

$

150,487

$

(105,030

)

(70

%)

Net product revenue for the third quarter of 2026 was $45.5 million, compared to $150.5 million for the third quarter of 2025, a decrease of $105.0 million, or 70%. The decrease in net product revenue was driven by a decrease of $103.3 million, or 73%, in net product revenue for Advanced Wound Care products.

Gross profit for the third quarter of 2026 was $23.6 million, or 52% of net product revenue, compared to $114.2 million, or 76% of net product revenue for the third quarter of 2025, a decrease of $90.7 million, or 79%.

Operating expenses for the third quarter of 2026 were $74.9 million compared to $130.1 million for the third quarter of 2025, a decrease of $55.2 million, or 42%. Cost of goods sold was $21.9 million for the third quarter of 2026, compared to $36.3 million for the third quarter of 2025, a decrease of $14.4 million, or 40%. Selling, general and administrative expenses were $45.1 million for the third quarter of 2026, compared to $79.7 million for the third quarter of 2025, a decrease of $34.7 million, or 43%. R&D expense was $8.0 million for the third quarter of 2026, compared to $13.2 million for the third quarter of 2025, a decrease of $5.3 million, or 40%.

Operating loss for the third quarter of 2026 was $29.5 million, compared to an operating income of $20.7 million for the third quarter of 2025, an increase in operating loss of $50.2 million.

Total other expense, net, for the third quarter of 2026 was $0.1 million, compared to total other income, net, of $0.4 million for the third quarter of 2025, a decrease of $0.6 million.

Net loss for the third quarter of 2026 was $29.6 million, or $(0.25) per share, compared to net income of $21.6 million, or $0.11 per share, for the third quarter of 2025, an increase in net loss of $51.2 million, or $(0.36) per share.

Adjusted net loss was $29.3 million for the third quarter of 2026, compared to adjusted net income of $23.2 million for the third quarter of 2025, an increase in adjusted net loss of $52.5 million.

Adjusted EBITDA loss was $22.4 million for the third quarter of 2026, compared to Adjusted EBITDA income of $30.1 million for the third quarter of 2025, an increase in Adjusted EBITDA loss of $52.5 million.

Non-GAAP operating loss was $29.1 million for the third quarter of 2026, compared to non-GAAP operating income of $23.0 million for the third quarter of 2025, an increase in non-GAAP operating loss of $52.1 mill

SEC.gov | Request Rate Threshold Exceeded

U.S. Securities and Exchange Commission

You’ve Exceeded the SEC’s Traffic Limit

Your request rate has exceeded the SEC’s maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes.

Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains available to all users, we reserve the right to block IP addresses that submit excessive requests.

The block will be lifted automatically by waiting 10 minutes. Continuing to exceed the SEC’s maximum allowable request rate during the time-out period will extend the duration of the time-out period. To ensure fair access for all users, please reduce the rate of your requests and visit SEC.gov again after the 10 minute time-out period has passed.

For best practices on efficiently downloading information from SEC.gov, including the latest EDGAR filings, visit sec.gov/developer. You can also sign up for email updates on the SEC open data program, including best practices that make it more efficient to download data, and SEC.gov enhancements that may impact scripted downloading processes. For more information, contact opendata@sec.gov.

For more information, please see the SEC’s Web Site Privacy and Security Policy. Thank you for your interest in the U.S. Securities and Exchange Commission.

Reference ID: 0.e618d017.1784725704.7cfcdb1

More Information

Internet Security Policy

By using this site, you are agreeing to security monitoring and auditing. For security purposes, and to ensure that the public service remains available to users, this government computer system employs programs to monitor network traffic to identify unauthorized attempts to upload or change information or to otherwise cause damage, including attempts to deny service to users.

Unauthorized attempts to upload information and/or change information on any portion of this site are strictly prohibited and are subject to prosecution under the Computer Fraud and Abuse Act of 1986 and the National Information Infrastructure Protection Act of 1996 (see Title 18 U.S.C. §§ 1001 and 1030).

To ensure our website performs well for all users, the SEC monitors the frequency of requests for SEC.gov content to ensure automated searches do not impact the ability of others to access SEC.gov content. We reserve the right to block IP addresses that submit excessive requests. Current guidelines limit users to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests.

If a user or application submits more than 10 requests per second, further requests from the IP address(es) may be limited for a brief period. Once the rate of requests has dropped below the threshold for 10 minutes, the user may resume accessing content on SEC.gov. This SEC practice is designed to limit excessive automated searches on SEC.gov and is not intended or expected to impact individuals browsing the SEC.gov website.

Note that this policy may change as the SEC manages SEC.gov to ensure that the website performs efficiently and remains available to all users.

Note: We do not offer technical support for developing or debugging scripted downloading processes.